The influence of socioeconomic status on access to cancer care and survival in resectable pancreatic cancer: a systematic review and meta-analysis

被引:3
|
作者
Petric, Josipa [1 ]
Handshin, Samuel [2 ]
Jonnada, Pavan Kumar [3 ]
Karunakaran, Monish [2 ,4 ]
Barreto, Savio George [2 ,5 ]
机构
[1] Flinders Med Ctr, Dept Surg, Adelaide, SA, Australia
[2] Flinders Univ S Australia, Coll Med & Publ Hlth, Adelaide, SA, Australia
[3] Basavatarakam Indoamer Canc Hosp & Res Inst, Dept Surg Oncol, Hyderabad, India
[4] Asian Inst Gastroenterol, Dept Surg Gastroenterol, Hyderabad, India
[5] Flinders Med Ctr, Div Surg & Perioperat Med, Adelaide, SA, Australia
关键词
outcomes; pancreaticoduodenectomy; survival; INSURANCE STATUS; DISPARITIES; RESECTION; STAGE; ADENOCARCINOMA; EQUITY; IMPACT; RACE;
D O I
10.1111/ans.17964
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Socioeconomic status (SES) is an important factor affecting access to cancer care and survival. Its role in pancreatic cancer warrants scrutiny. Methods A systematic review of major reference databases was undertaken. Categorization of the study population into low SES (LSES) and high SES (HSES) was based on the criteria employed in the individual studies. The outcome measures studied were stage of cancer presentation, access to care and overall survival. Meta-analysis was performed using random-effects models and trial sequential analysis (TSA) was used to assess the precision and conclusiveness of the results. Results Thirteen studies meeting inclusion criteria were included in the meta-analysis, which demonstrated that LSES was associated with significantly lower rates of presentation at a non-metastatic stage and poorer access to cancer care, viz. surgery, chemotherapy and radiation therapy. Despite heterogeneity, TSA supported the findings, displaying minimal type I error. Conclusion As LSES is associated with delayed presentation, poorer access to care and poorer survival, SES should be considered a modifiable risk factor for poor outcomes in pancreatic cancer.
引用
收藏
页码:2795 / 2807
页数:13
相关论文
共 50 条
  • [21] Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review
    Ren, Xiaohan
    Wei, Xiyi
    Ding, Yichao
    Qi, Feng
    Zhang, Yundi
    Hu, Xin
    Qin, Chao
    Li, Xiao
    ONCOTARGETS AND THERAPY, 2019, 12 : 733 - 744
  • [22] Sarcopenia in Pancreatic Cancer: A systematic Review and Meta-Analysis
    Bundred, J.
    Kamarajah, S.
    Roberts, K. J.
    BRITISH JOURNAL OF SURGERY, 2019, 106 : 6 - 6
  • [23] Does neoadjuvant treatment in resectable pancreatic cancer improve overall survival? A systematic review and meta-analysis of randomized controlled trials
    Uson, P. L. S.
    Silva, D. Dias e
    de Castro, N. M.
    da Silva Victor, E.
    Rother, E. T.
    Araujo, S. E. A.
    Borad, M. J.
    Moura, F.
    ESMO OPEN, 2023, 8 (01)
  • [24] Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis
    Liu, Shi
    Liu, Ying
    Yang, Jian
    Dos Santos, Troy
    Yang, Lili
    Li, Min
    Jiang, Qingfeng
    Ma, Changming
    TRANSLATIONAL ONCOLOGY, 2021, 14 (08):
  • [25] Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis
    Si-qi Yang
    Rui-qi Zou
    Yu-shi Dai
    Fu-yu Li
    Hai-jie Hu
    Updates in Surgery, 2024, 76 : 1 - 15
  • [26] Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
    Quisette P. Janssen
    Jacob L. van Dam
    Isabelle G. Kivits
    Marc G. Besselink
    Casper H. J. van Eijck
    Marjolein Y. V. Homs
    Joost J. M. E. Nuyttens
    Hongchao Qi
    Hjalmar J. van Santvoort
    Alice C. Wei
    Roeland F. de Wilde
    Johanna W. Wilmink
    Geertjan van Tienhoven
    Bas Groot Koerkamp
    Annals of Surgical Oncology, 2021, 28 : 8297 - 8308
  • [27] Added Value of Radiotherapy Following Neoadjuvant FOLFIRINOX for Resectable and Borderline Resectable Pancreatic Cancer: A Systematic Review and Meta-Analysis
    Janssen, Quisette P.
    van Dam, Jacob L.
    Kivits, Isabelle G.
    Besselink, Marc G.
    van Eijck, Casper H. J.
    Homs, Marjolein Y. V.
    Nuyttens, Joost J. M. E.
    Qi, Hongchao
    van Santvoort, Hjalmar J.
    Wei, Alice C.
    de Wilde, Roeland F.
    Wilmink, Johanna W.
    van Tienhoven, Geertjan
    Groot Koerkamp, Bas
    ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (13) : 8297 - 8308
  • [28] Comparison of the upfront surgery and neoadjuvant therapy in resectable and borderline resectable pancreatic cancer: an updated systematic review and meta-analysis
    Yang, Si-qi
    Zou, Rui-qi
    Dai, Yu-shi
    Li, Fu-yu
    Hu, Hai-jie
    UPDATES IN SURGERY, 2024, 76 (01) : 1 - 15
  • [29] Survival benefits of neoadjuvant chemo(radio)therapy versus surgery first in patients with resectable or borderline resectable pancreatic cancer: a systematic review and meta-analysis
    Pan, Long
    Fang, Jing
    Tong, Chenhao
    Chen, Mingyu
    Zhang, Bin
    Juengpanich, Sarun
    Wang, Yifan
    Cai, Xiujun
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2020, 18 (01)
  • [30] Adiposity and cancer survival: a systematic review and meta-analysis
    Cheng, En
    Kirley, Jocelyn
    Feliciano, Elizabeth M. Cespedes
    Caan, Bette J.
    CANCER CAUSES & CONTROL, 2022, 33 (10) : 1219 - 1246